Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Barrett-Lee

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Current Medical Research and Opinion|May 11, 2006
Iron and the anaemia of chronic disease: a review and strategic recommendationsIvor Cavill, Michael Auerbach, George R Bailie, et al.
Trials|October 11, 2013
QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonatesAnnmarie Nelson, Debbie Fenlon, Jenny Morris, et al.
Trials|March 10, 2017
The use of randomisation-based efficacy estimators in non-inferiority trialsDavid Gillespie, Daniel Farewell, Peter Barrett-Lee, et al.
BMC Cancer|October 9, 2012
Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronanStephen Hiscox, Bedanta Baruha, Chris Smith, et al.
The Lancet. Oncology|December 17, 2013
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trialPeter Barrett-Lee, Angela Casbard, Jacinta Abraham, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2004
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsHeinz Ludwig, Simon Van Belle, Peter Barrett-Lee, et al.
Breast Cancer Research : BCR|March 16, 2012
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancerIsabel Pinhel, Margaret Hills, Suzanne Drury, et al.
The Oncologist|August 28, 2010
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trialPaolo Pronzato, Enrico Cortesi, Carin C van der Rijt, et al.
The Lancet. Oncology|August 23, 2013
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyXavier Pivot, Joseph Gligorov, Volkmar Müller, et al.
The Lancet. Oncology|July 19, 2014
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trialRobert Coleman, David Cameron, David Dodwell, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Current Medical Research and Opinion|May 11, 2006
Iron and the anaemia of chronic disease: a review and strategic recommendationsIvor Cavill, Michael Auerbach, George R Bailie, et al.
Trials|October 11, 2013
QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonatesAnnmarie Nelson, Debbie Fenlon, Jenny Morris, et al.
Trials|March 10, 2017
The use of randomisation-based efficacy estimators in non-inferiority trialsDavid Gillespie, Daniel Farewell, Peter Barrett-Lee, et al.
BMC Cancer|October 9, 2012
Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronanStephen Hiscox, Bedanta Baruha, Chris Smith, et al.
The Lancet. Oncology|December 17, 2013
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trialPeter Barrett-Lee, Angela Casbard, Jacinta Abraham, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2004
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsHeinz Ludwig, Simon Van Belle, Peter Barrett-Lee, et al.
Breast Cancer Research : BCR|March 16, 2012
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancerIsabel Pinhel, Margaret Hills, Suzanne Drury, et al.
The Oncologist|August 28, 2010
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trialPaolo Pronzato, Enrico Cortesi, Carin C van der Rijt, et al.
The Lancet. Oncology|August 23, 2013
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyXavier Pivot, Joseph Gligorov, Volkmar Müller, et al.
The Lancet. Oncology|July 19, 2014
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trialRobert Coleman, David Cameron, David Dodwell, et al.
Pageof 4